NCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
Clinical Trials
543 trialsNCT05623150 2026-04-16
CHALNA2
Institut National de la Santé Et de la Recherche Médicale, France
Recruiting
NCT05842174 2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2 Recruiting
NCT06066138 2026-04-16
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07476651 2026-04-16
LASER
Seoul National University Hospital
Phase NA Recruiting
NCT07490262 2026-04-16
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3 Recruiting
NCT05143619 2026-04-15
Impact of "Teaching the Teachers" Concept on Global Education and Application of Hepatocellular Carcinoma Diagnosis Guidelines
M.D. Anderson Cancer Center
Recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06427941 2026-04-15
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06764316 2026-04-15
BANTAM-01
Bayer
Phase 1 Recruiting
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07164313 2026-04-14
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT07291076 2026-04-14
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06426992 2026-04-13
Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
Seoul National University Hospital
Phase NA Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06726161 2026-04-13
GPC3
RayzeBio, Inc.
Phase 1/2 Recruiting
NCT06811116 2026-04-13
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06938945 2026-04-13
Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
Peking University
Phase NA Recruiting
NCT06995898 2026-04-13
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT07521852 2026-04-13
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT06944483 2026-04-09
ISTAR-01
Seoul National University Hospital
Recruiting
NCT06979219 2026-04-09
ISTAR-02
Seoul National University Hospital
Recruiting
NCT07293468 2026-04-09
BIIRTH
Tuen Mun Hospital
Phase 2/3 Recruiting
NCT07419841 2026-04-09
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07227012 2026-04-08
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
Phase 1/2 Recruiting
NCT05003895 2026-04-07
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05440708 2026-04-06
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
Phase 1/2 Recruiting
NCT06795022 2026-04-06
RHEA-1
AstraZeneca
Phase 1/2 Recruiting
NCT06096779 2026-04-03
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT06342414 2026-04-03
ELUCIDATE
City of Hope Medical Center
Recruiting
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune Inc.
Phase 2 Recruiting
NCT06553885 2026-04-01
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07062055 2026-04-01
BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + SBRT for BCLC-C HCC With PVTT and/or Oligometastases
Shandong Cancer Hospital and Institute
Phase 2 Recruiting
NCT06486454 2026-03-31
Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study)
HistoSonics, Inc.
Recruiting
NCT06600321 2026-03-31
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Alnylam Pharmaceuticals
Phase 1 Recruiting
NCT07312292 2026-03-30
RADIANT
UMC Utrecht
Phase 2 Recruiting
NCT07377487 2026-03-30
INDIGO
Boston Scientific Corporation
Phase NA Recruiting
NCT04390724 2026-03-27
Optimizing Y90 Therapy for Radiation Lobectomy
Northwestern University
Recruiting
NCT06503146 2026-03-27
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06687941 2026-03-27
A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
Aptamer Sciences, Inc.
Phase 1 Recruiting
NCT06902246 2026-03-27
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
University of Miami
Phase 2 Recruiting
NCT07284121 2026-03-27
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
Recruiting
NCT07331883 2026-03-27
Sintilimab Combined With Bevacizumab Biosimilar as Adjuvant Treatment After Resection of Ruptured Hepatocellular Carcinoma (CLEAR-2)
Ruijin Hospital
Phase 2 Recruiting
NCT07495215 2026-03-27
A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection
Sir Run Run Shaw Hospital
Phase 1/2 Recruiting